SCHEMBL30355393

SCHEMBL30355393

CCC1(CC)CC(=O)c2cc(-c3nc(-c4ccc(S(=O)(=O)NC)cc4)no3)ccc2O1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 5/20 0.37
▸ CA9 Q16790 5/20 0.37
▸ CA12 O43570 3/20 0.37
▸ CA1 P00915 3/20 0.37
▸ BMP1 P13497 1/20 0.37
▸ S1PR1 P21453 5/20 0.36
▸ CNR1 P21554 1/20 0.35
▸ CNR2 P34972 1/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ MAPT P10636 3/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23524366 1.00 CA2 (0.37) CA2CA9CA12CA1BMP1
SCHEMBL23524295 0.89 CA9 (0.50) CA2CA9CA12CA1S1PR1
SCHEMBL30355587 0.89 CA9 (0.50) CA2CA9CA12CA1S1PR1
SCHEMBL30355448 0.87 HDAC4 (0.43) CA2CA9CA12CA1S1PR1
SCHEMBL23524153 0.87 HDAC4 (0.43) CA2CA9CA12CA1S1PR1
SCHEMBL23523852 0.86 NPC1 (0.37) S1PR1CNR1CNR2NPC1RAB9A
SCHEMBL30355763 0.86 NPC1 (0.37) S1PR1CNR1CNR2NPC1RAB9A
SCHEMBL23523716 0.85 NPC1 (0.43) NPC1RAB9ASMN1; SMN2MEN1PKM
SCHEMBL30355571 0.85 NPC1 (0.43) NPC1RAB9ASMN1; SMN2MEN1PKM
SCHEMBL23524045 0.85 KCNH2 (0.40) BMP1KMT2AMAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same TREVENA, INC. (US) 2024-02-27 — — US disclosed
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME TREVENA, INC. 2023-07-27 — — US disclosed
US-20230114241-A1 METHODS OF TREATING EPILEPSY USING THE SAME TREVENA, INC. 2023-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME S1PR1, S1PR2, S1PR3 CA2 3359/4885CA9 4628/4885CA12 4698/4885
US-20230114241-A1 METHODS OF TREATING EPILEPSY USING THE SAME S1PR1, S1PR2, S1PR3 CA2 825/4885CA9 3668/4885CA12 2815/4885
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same S1PR1, S1PR2, S1PR3 CA2 3359/4885CA9 4628/4885CA12 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback